

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/612,600	07/01/2003	Neil T. Parkin	011068-015-999	4526
7590 10/19/2006		EXAMINER		
JONES DAY			PARKIN, JEFFREY S	
222 East 41st Street New York, NY 10017-6702			ART UNIT	PAPER NUMBER
			1648	
			DATE MAILED: 10/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

Ċv	
V	

•	Application No.	Applicant(s)					
	10/612,600	PARKIN ET AL.					
Office Action Summary	Examiner	Art Unit					
·	Jeffrey S. Parkin, Ph.D.	1648					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status		·					
1) Responsive to communication(s) filed on 31 Ju	Responsive to communication(s) filed on 31 July 2006.						
· · · · · · · · · · · · · · · · · · ·							
3) Since this application is in condition for allowan	ice except for formal matters, pro	secution as to the merits is					
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) 1-21 is/are pending in the application.							
	4a) Of the above claim(s) <u>5,8-17,20 and 21</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) 1-4,6,7,18 and 19 is/are rejected.	<u> </u>						
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	election requirement.						
Application Papers							
9) The specification is objected to by the Examiner	-						
10)⊠ The drawing(s) filed on <u>01 July 2003</u> is/are: a)		v the Examiner					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
_							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)	·						
1) X Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te					
B) ☑ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>05/19/2004;07/14/2004</u> . 5) ☑ Notice of Informal Patent Application 6) ☑ Other:							
т фот то(зуттап васе <u>од таггооч, от тчггооч.</u>							

Serial No.: 10/612,600 Docket No.: 011068-015-999
Applicants: Parkin, N. T., et al. Filing Date: 07/01/2003

Detailed Office Action

Status of the Claims

Applicants' election of Group I (claims 1-4, 6, 7, 18, and 19) with traverse in the communication filed 31 July, 2006, is The traversal is based upon the premise that it acknowledged. is inappropriate to restrict multiple inventions set forth in the same claim pursuant to the doctrine set forth in In re Weber, Soder, and Boksay, 198 U.S.P.Q. 328 (C.C.P.A., 1978). Applicants further argue that it would constitute an undue burden on applicants to file multiple applications stemming from the restriction requirement. Finally, applicants submit that a species election should be performed instead of a restriction requirement. This is not found persuasive for the reasons of record set forth in the last office action. As noted in the last office action, each protease inhibitor is structurally different with disparate physicochemical properties activities. The utilization of each protease in the claimed methodology constitutes an independent and distinct invention. Additional protease inhibitors will not be rejoined because they lack unity of invention as required under In re Harnisch, 631 F.2d 716, 206 U.S.P.Q. 300 (C.C.P.A. 1980) and Ex parte Hozumi, 3 U.S.P.Q.2d 1059 (Bd. Pat. App. & Int. 1984). Briefly, unity of invention exists where compounds included within a Markush group (1) share a common utility, and (2) share a substantial structural feature essential to that utility. As set forth clearly in the restriction requirement, each of the identified protease inhibitors contains a different structure and associated with different mutational changes in protease

U.S. Serial No.: 10/612,600 Applicants: Parkin, N. T., et al.

resistant strains. Accordingly the requirement is still deemed to be proper and is therefore made FINAL. Claims 5, 8-17, 20, and 21 are withdrawn from further consideration by the examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention.

37 C.F.R. § 1.98

The information disclosure statements filed 19 May, 2004, and 14 July, 2004, have been placed in the application file and the information referred to therein has been considered.

35 U.S.C. § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4, 6, 7, 18, and 19 are rejected under 35 U.S.C. § 102(b) as being anticipated by Parkin et al. (2000). Parkin and colleagues provide a method for assessing the likelihood of HIV-1 being hypersusceptible to treatment with amprenavir (APV/AMP). The authors detected multiple mutations (e.g., K20I/M36I) that were associated with hypersusceptibility to treatment. The study also involved patients that had undergone prior treatment with another antiviral. Thus, this teaching meets all of the claimed limitations.

U.S. Serial No.: 10/612,600 Applicants: Parkin, N. T., et al.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Office (Office) Trademark requires most patent correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on

U.S. Serial No.: 10/612,600 Applicants: Parkin, N. T., et al.

access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Jeffrey S. Parkin, Ph.D.

Primary Examiner Art Unit 1648

16 October, 2006